Distinct histone modifications denote early stress-induced drug tolerance in cancer

Abdullah Al Emran, Diego M. Marzese, Dinoop Ravindran Menon, Mitchell S. Stark, Joachim Torrano, Heinz Hammerlindl, Gao Zhang, Patricia Brafford, Matthew P. Salomon, Nellie Nelson, Sabrina Hammerlindl, Deepesh Gupta, Gordon B. Mills, Yiling Lu, Richard A. Sturm, Keith Flaherty, S. B.Hoon Dave, Brian Gabrielli, Meenhard Herlyn, Helmut Schaider

    Research output: Contribution to journalArticle

    16 Scopus citations

    Abstract

    Besides somatic mutations or drug efflux, epigenetic reprogramming can lead to acquired drug resistance. We recently have identified early stress-induced multi-drug tolerant cancer cells termed induced drug-tolerant cells (IDTCs). Here, IDTCs were generated using different types of cancer cell lines; melanoma, lung, breast and colon cancer. A common loss of the H3K4me3 and H3K27me3 and gain of H3K9me3 mark was observed as a significant response to drug exposure or nutrient starvation in IDTCs. These epigenetic changes were reversible upon drug holidays. Microarray, qRT-PCR and protein expression data confirmed the up-regulation of histone methyltransferases (SETDB1 and SETDB2) which contribute to the accumulation of H3K9me3 concomitantly in the different cancer types. Genome-wide studies suggest that transcriptional repression of genes is due to concordant loss of H3K4me3 and regional increment of H3K9me3. Conversely, genome-wide CpG site-specific DNA methylation showed no common changes at the IDTC state. This suggests that distinct histone methylation patterns rather than DNA methylation are driving the transition from parental to IDTCs. In addition, silencing of SETDB1/2 reversed multi drug tolerance. Alterations of histone marks in early multi-drug tolerance with an increment in H3K9me3 and loss of H3K4me3/H3K27me3 is neither exclusive for any particular stress response nor cancer type specific but rather a generic response.

    Original languageEnglish (US)
    Pages (from-to)8206-8222
    Number of pages17
    JournalOncotarget
    Volume9
    Issue number9
    DOIs
    StatePublished - Jan 1 2018

    Keywords

    • Acquired drug resistance
    • Dna methylation
    • Epigenetic reprogramming
    • Histone modification
    • Stress-induced resistance

    ASJC Scopus subject areas

    • Oncology

    Fingerprint Dive into the research topics of 'Distinct histone modifications denote early stress-induced drug tolerance in cancer'. Together they form a unique fingerprint.

  • Cite this

    Emran, A. A., Marzese, D. M., Menon, D. R., Stark, M. S., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P., Salomon, M. P., Nelson, N., Hammerlindl, S., Gupta, D., Mills, G. B., Lu, Y., Sturm, R. A., Flaherty, K., Dave, S. B. H., Gabrielli, B., Herlyn, M., & Schaider, H. (2018). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9(9), 8206-8222. https://doi.org/10.18632/oncotarget.23654